FORT WORTH, Texas -- (BUSINESS WIRE) --
Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will be attending the 2022 American Academy of Dermatology Annual Meeting to showcase its latest approved and investigational product updates. This includes clinical data presentations at its product theaters, advisory boards, and booth activities onsite as AAD returns in-person once more.
“We are excited to attend AAD to connect with the dermatology community and showcase our latest innovation and data across our complete dermatology portfolio,” said Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma. “Our presence underscores our commitment to developing and bringing to market dermatological solutions to address every skin need.”
A considerable amount of new data will be presented during the AAD Congress in the form of abstracts and oral presentations for nemolizumab, a first-in-class investigational monoclonal antibody directed against the interleukin-31 (IL-31) receptor, under clinical development for the treatment of atopic dermatitis and prurigo nodularis.
The data for prurigo nodularis include efficacy data of nemolizumab and its impact on itch and sleep disturbance. An additional seven abstracts look at a variety of aspects of the disease including its prevalence, current treatment practices and the effect of the disease on sleep, mental health disorders and gastrointestinal and hepatobiliary diseases. Three abstracts in atopic dermatitis look at the safety and efficacy of nemolizumab in adolescents and the impact of nemolizumab according to EASI and Scorad components.
Galderma will present thirteen study abstracts regarding its investigational monoclonal antibody that targets the IL-31 receptor, nemolizumab. Data comes from Phase 2 studies and real-world evidence. More details on Galderma’s activities can be found below.
| Abstract # and Title | First Author | Presentation Date/Time (ET) |
| Abstract #35226: Characterization of Pain in Prurigo Nodularis: An Online Survey-Based Study | Prachi Aggarwal, BA | Friday, March 25, 8:35 – 8:40 AM |
| Abstract #35303: Treatment Practices and the Use of Web-based Resources in Prurigo Nodularis | Prachi Aggarwal, BA | Friday, March 25, 8:40 – 8:45 AM |
| Abstract #35351: Association between prurigo nodularis and gastrointestinal and hepatobiliary diseases in adults: A national cross-sectional study. | Adawi Waleed | Friday, March 25, 8:55 – 9:00 AM |
| Abstract #35165: Efficacy, Tolerability, and Cosmetic Acceptability of an Acne Regimen Specifically Designed for Sensitive Skin | James Q. Del Rosso, DO |
Friday, March 25
8:55 – 9:00 AM |
| Abstract #32846: DUAL Study: Trifarotene Plus Doxycycline Has Proven Efficacy and Safety in Severe Acne Vulgaris | James Q. Del Rosso, DO |
Friday, March 25
9:00 – 9:05 AM |
| Abstract #33284: Efficacy of nemolizumab in atopic dermatitis: Rapid impact on EASI and SCORAD components |
Jean-David Bouaziz, MD, PhD
|
Friday, March 25 11:15 – 11:20 AM |
| Abstract #33317: Study of nemolizumab pharmacokinetics, safety, and efficacy in adolescents with atopic dermatitis |
Robert Sidbury, MD, MPH
|
Friday, March 25 11:20 – 11:25 AM |
| Abstract #34945: An In-vitro Evaluation of a Niacinamide-Panthenol-Glycerin Complex on Skin Barrier Function, Hydration, and Neuro-Inflammation | Dillon Nussbaum, BSc | Friday, March 25 11:55 – 12:00 PM |
| Abstract #34679: Association of adult atopic dermatitis severity with decreased physical activity: A cross-sectional study | Gabrielle Schwartzman |
Friday, March 25
2:20 – 2:25 PM |
| Abstract #35218: Sleep disturbance in adults with prurigo nodularis is associated with increased circulating C-reactive protein levels and adverse cardiovascular outcomes | Varsha Parthasarathy | Friday, March 25, 2:25 – 2:30 PM |
| Abstract #33202: Prurigo nodularis and mental health disorders among hospitalized patients in the United States | Thomas K Le | Saturday, March 26, 1:25 – 1:30 PM |
| Abstract #34095: Observed and Projected Prevalence of Prurigo Nodularis in a Commercially and Medicare-insured U.S. Population | Shawn G. Kwatra | Saturday, March 26, 2:40 – 2:45 PM |
| Abstract #33307: Nemolizumab is associated with a rapid reduction of itch and sleep disturbance in patients with prurigo nodularis |
Sonja Ständer, MD
|
E-Poster |
